Molecular magnetic resonance imaging of activated platelets allows noninvasive detection of early myocarditis in mice.
Animals
Binding Sites
Blood Platelets
Cardiomyopathies
/ diagnostic imaging
Contrast Media
/ administration & dosage
Disease Models, Animal
Early Diagnosis
Humans
Integrin beta3
/ metabolism
Magnetic Resonance Imaging
Male
Mice
Mice, Inbred BALB C
Myocarditis
/ diagnostic imaging
Platelet Activation
Platelet Membrane Glycoprotein IIb
/ metabolism
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 08 2020
06 08 2020
Historique:
received:
05
03
2020
accepted:
22
07
2020
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
18
12
2020
Statut:
epublish
Résumé
MRI sensitivity for diagnosis and localization of early myocarditis is limited, although it is of central clinical interest. The aim of this project was to test a contrast agent targeting activated platelets consisting of microparticles of iron oxide (MPIO) conjugated to a single-chain antibody directed against ligand-induced binding sites (LIBS) of activated glycoprotein IIb/IIIa (= LIBS-MPIO). Myocarditis was induced by subcutaneous injection of an emulsion of porcine cardiac myosin and complete Freund's adjuvant in mice. 3D 7 T in-vivo MRI showed focal signal effects in LIBS-MPIO injected mice 2 days after induction of myocarditis, whereas in control-MPIO injected mice no signal was detectable. Histology confirmed CD41-positive staining, indicating platelet involvement in myocarditis in mice as well as in human specimens with significantly higher LIBS-MPIO binding compared to control-MPIO in both species. Quantification of the myocardial MRI signal confirmed a signal decrease after LIBS-MPIO injection and significant less signal in comparison to control-MPIO injection. These data show, that platelets are involved in inflammation during the course of myocarditis in mice and humans. They can be imaged non-invasively with LIBS-MPIO by molecular MRI at an early time point of the inflammation in mice, which is a valuable approach for preclinical models and of interest for both diagnostic and prognostic purposes.
Identifiants
pubmed: 32764735
doi: 10.1038/s41598-020-70043-9
pii: 10.1038/s41598-020-70043-9
pmc: PMC7413393
doi:
Substances chimiques
Contrast Media
0
Integrin beta3
0
Platelet Membrane Glycoprotein IIb
0
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13211Références
Caforio, A. L. P. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J.34(2636–2648), 2648a–2648d (2013).
Aretz, H. T. et al. Myocarditis. A histopathologic definition and classification. Am. J. Cardiovasc. Pathol.1, 3–14 (1987).
pubmed: 3455232
Ferreira, V. M. et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: Expert recommendations. J. Am. Coll. Cardiol.72, 3158–3176 (2018).
doi: 10.1016/j.jacc.2018.09.072
von Elverfeldt, D. et al. Dual-contrast molecular imaging allows noninvasive characterization of myocardial ischemia/reperfusion injury after coronary vessel occlusion in mice by magnetic resonance imaging. Circulation130, 676–687 (2014).
doi: 10.1161/CIRCULATIONAHA.113.008157
Schwarz, M. et al. Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61). J. Pharmacol. Exp. Ther.308, 1002–1011 (2004).
doi: 10.1124/jpet.103.058883
Stoll, P. et al. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscler. Thromb. Vasc. Biol.27, 1206–1212 (2007).
doi: 10.1161/ATVBAHA.106.138875
Schwarz, M. et al. Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alphaIIbbeta3 designed by subtractive selection from naive human phage libraries. FASEB J.18, 1704–1706 (2004).
doi: 10.1096/fj.04-1513fje
Schwarz, M. et al. Conformation-specific blockade of the integrin GPIIb/IIIa: A novel antiplatelet strategy that selectively targets activated platelets. Circ. Res.99, 25–33 (2006).
doi: 10.1161/01.RES.0000232317.84122.0c
von Zur Muhlen, C. et al. A contrast agent recognizing activated platelets reveals murine cerebral malaria pathology undetectable by conventional MRI. J. Clin. Invest.118, 1198–1207 (2008).
von zur Muhlen, C. et al. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation118, 258–267 (2008).
doi: 10.1161/CIRCULATIONAHA.107.753657
von zur Muhlen, C. et al. Visualization of activated platelets by targeted magnetic resonance imaging utilizing conformation-specific antibodies against glycoprotein IIb/IIIa. J. Vasc. Res.46, 6–14 (2009).
doi: 10.1159/000135660
Duerschmied, D. et al. Molecular magnetic resonance imaging allows the detection of activated platelets in a new mouse model of coronary artery thrombosis. Invest. Radiol.46, 618–623 (2011).
doi: 10.1097/RLI.0b013e31821e62fb
Heidt, T. et al. Molecular imaging of activated platelets allows the detection of pulmonary embolism with magnetic resonance imaging. Sci. Rep.6, 25044 (2016).
doi: 10.1038/srep25044
Ziegler, M. et al. Highly sensitive detection of minimal cardiac ischemia using positron emission tomography imaging of activated platelets. Sci. Rep.6, 38161 (2016).
doi: 10.1038/srep38161
Wang, X. et al. Thrombus-targeted theranostic microbubbles: A new technology towards concurrent rapid ultrasound diagnosis and bleeding-free fibrinolytic treatment of thrombosis. Theranostics6, 726–738 (2016).
doi: 10.7150/thno.14514
Wang, X. et al. Novel single-chain antibody-targeted microbubbles for molecular ultrasound imaging of thrombosis: validation of a unique noninvasive method for rapid and sensitive detection of thrombi and monitoring of success or failure of thrombolysis in mice. Circulation125, 3117–3126 (2012).
doi: 10.1161/CIRCULATIONAHA.111.030312
Maier, A. et al. A molecular intravascular ultrasound contrast agent allows detection of activated platelets on the surface of symptomatic human plaques. Atherosclerosis267, 68–77 (2017).
doi: 10.1016/j.atherosclerosis.2017.10.029
Lim, B. et al. A unique recombinant fluoroprobe targeting activated platelets allows in vivo detection of arterial thrombosis and pulmonary embolism using a novel three-dimensional fluorescence emission computed tomography (FLECT) technology. Theranostics7, 1047–1061 (2017).
doi: 10.7150/thno.18099
Gawaz, M., Langer, H. & May, A. E. Platelets in inflammation and atherogenesis. J. Clin. Invest.115, 3378–3384 (2005).
doi: 10.1172/JCI27196
Jenne, C. N. & Kubes, P. Platelets in inflammation and infection. Platelets26, 286–292 (2015).
doi: 10.3109/09537104.2015.1010441
Ziegler, M., Wang, X. & Peter, K. Platelets in cardiac ischaemia/reperfusion injury: A promising therapeutic target. Cardiovasc. Res.115, 1178–1188 (2019).
doi: 10.1093/cvr/cvz070
Steinl, D. C. et al. Noninvasive contrast-enhanced ultrasound molecular imaging detects myocardial inflammatory response in autoimmune myocarditis. Circ. Cardiovasc. Imaging9, 2 (2016).
doi: 10.1161/CIRCIMAGING.116.004720
Liu, W. et al. Thioredoxin-1 ameliorates myosin-induced autoimmune myocarditis by suppressing chemokine expressions and leukocyte chemotaxis in mice. Circulation110, 1276–1283 (2004).
doi: 10.1161/01.CIR.0000141803.41217.B6
Muller, A.-M., Fischer, A., Katus, H. A. & Kaya, Z. Mouse models of autoimmune diseases—autoimmune myocarditis. Curr. Pharm. Des.21, 2498–2512 (2015).
doi: 10.2174/1381612821666150316123711
Braig, M. et al. Preclinical 4D-flow magnetic resonance phase contrast imaging of the murine aortic arch. PLoS ONE12, e0187596 (2017).
doi: 10.1371/journal.pone.0187596
Jacoby, C. et al. Visualization of immune cell infiltration in experimental viral myocarditis by (19)F MRI in vivo. Magma N. Y. N27, 101–106 (2014).
doi: 10.1007/s10334-013-0391-6
van Heeswijk, R. B. et al. Selective in vivo visualization of immune-cell infiltration in a mouse model of autoimmune myocarditis by fluorine-19 cardiac magnetic resonance. Circ. Cardiovasc. Imaging6, 277–284 (2013).
doi: 10.1161/CIRCIMAGING.112.000125
Leuschner, F. et al. Silencing of CCR2 in myocarditis. Eur. Heart J.36, 1478–1488 (2015).
doi: 10.1093/eurheartj/ehu225
Helluy, X. et al. In vivo T2* weighted MRI visualizes cardiac lesions in murine models of acute and chronic viral myocarditis. PLoS ONE12, e0172084 (2017).
doi: 10.1371/journal.pone.0172084
Werner, R. A. et al. Longitudinal 18F-FDG PET imaging in a rat model of autoimmune myocarditis. Eur. Heart J. Cardiovasc. Imaging20, 467–474 (2019).
doi: 10.1093/ehjci/jey119
Maya, Y. et al. 11C-Methionine PET of myocardial inflammation in a rat model of experimental autoimmune myocarditis. J. Nucl. Med. Off. Publ. Soc. Nucl. Med.57, 1985–1990 (2016).
Abgral, R. et al. Clinical utility of combined FDG-PET/MR to assess myocardial disease. JACC Cardiovasc. Imaging10, 594–597 (2017).
doi: 10.1016/j.jcmg.2016.02.029
Nensa, F. et al. Feasibility of FDG-PET in myocarditis: Comparison to CMR using integrated PET/MRI. J. Nucl. Cardiol. Off. Publ. Am. Soc. Nucl. Cardiol.25, 785–794 (2018).
doi: 10.1007/s12350-016-0616-y
Siegel-Axel, D. I. & Gawaz, M. Platelets and endothelial cells. Semin. Thromb. Hemost.33, 128–135 (2007).
doi: 10.1055/s-2007-969025
Meier, S. et al. Immuno-magnetoliposomes targeting activated platelets as a potentially human-compatible MRI contrast agent for targeting atherothrombosis. Biomaterials53, 137–148 (2015).
doi: 10.1016/j.biomaterials.2015.02.088
Hagemeyer, C. E., von zur Muhlen, C., von Elverfeldt, D. & Peter, K. Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb. Haemost.101, 1012–1019 (2009).
doi: 10.1160/TH08-12-0816
Yilmaz, A. et al. Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: A human study using a multi-parametric cardiovascular magnetic resonance imaging approach. Eur. Heart J.34, 462–475 (2013).
doi: 10.1093/eurheartj/ehs366
von Muhlen, C. et al. Functionalized magnetic resonance contrast agent selectively binds to glycoprotein IIb/IIIa on activated human platelets under flow conditions and is detectable at clinically relevant field strengths. Mol. Imaging7, 59–67 (2008).